-

How Compounded Treatments Are Helping Hims & Hers Customers Meet Their Weight Loss Goals

Hims & Hers today released a white paper on how its customers are thriving and seeing meaningful results through personalized weight loss solutions

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today released a white paper entitled “Hims & Hers Weight Loss: A Look at Early Customer Experiences and Outcomes” which outlines how customers are achieving positive outcomes with compounded medications through our weight loss program. Early customer results indicate they are managing side effects well, staying on treatment, and overall feeling healthier.

The United States is in the midst of an obesity epidemic. 70% of American adults have obesity or are overweight. According to the World Health Organization (WHO), at least 2.8 million people die each year due to being overweight or obese. To help solve the obesity crisis in America, successful weight loss solutions are critical to helping patients prosper. We need weight loss solutions that can meet intense ongoing consumer demand, are cost-effective, and are tailored to individuals’ unique needs and sensitivities.

“We are laser focused on increasing access to world-class personalized care in the highest impact areas of health and wellness,” said Dr. Patrick Carroll, Chief Medical Officer of Hims & Hers. “With over 40% of our nation’s adults considered obese our country demands that we use our expertise, size, and industry leadership to answer the very real obesity crisis in the United States and be a part of the solution for the millions of Americans who have obesity and are looking for help.”

According to data highlighted in the company’s latest white paper, research shows that Hims & Hers weight loss solutions are helping customers achieve positive health outcomes. Key findings include:

  • Customers using oral medication kits on average, lost 7.5 pounds - approximately 3.6% of their initial body weight - in their first month.
  • Customers using compounded GLP-1s lost an average of 9.3 pounds - approximately 4.1% of their initial body weight - in their first month.
  • 79% of compounded GLP-1 customers reported that their treatment experience had met or exceeded their expectations.
  • 90% of compounded GLP-1 customers are satisfied with their personalized dosing plan and 87% reported they are progressing towards their weight loss goal, very close to meeting their weight loss goal, or had already achieved their weight loss goal.

The research also suggests that Hims & Hers’ weight loss offering is sustainable, allowing its customers to stay on their treatments and achieve lasting results.

  • Only 13% of compounded GLP-1 customers cancel their treatment subscription in the first month. This is significant when compared to a recent Blue Cross Blue Shield finding that over 30% of commercially insured adults prescribed GLP-1 treatment discontinue within the first four weeks, which may be because of discomfort with early side effects, the high cost of certain weight loss treatments, and limited access to care.
  • 80% of compounded GLP-1 customers who report side effects like nausea say the side effects are tolerable, indicating they plan to continue their treatment, despite mild side effects.

Since December 2023, Hims & Hers has provided its customers access to weight loss solutions. The Hims & Hers program offers a holistic, cost-effective, and personalized approach to reducing weight that includes:

  • Medication management: Following consultation with a licensed healthcare provider on the platform, patients may be prescribed medication that is personalized based upon individual patients’ weight loss goals, medical history, needs, and preferences.
  • Nutrition, exercise, and mental health support: Through the Hims & Hers app, patients have access to educational and motivational content that offers nutrition guidance, recipes, exercise recommendations, sleep advice, and mental health support. All content is personalized based on the individual’s lifestyle and appetite profile.
  • Digital tracking tools: Through the Hims & Hers app, patients can track their progress, hydration, movement, and sleep.
  • 24/7 access to a care team: Individuals can message their care team at any time through the Hims & Hers app.

“The data and insights we have been able to glean through our research show that our customers are having meaningful health outcomes when it comes to weight loss,” said Dr. Jessica Yu, Senior Director of Patient Experience at Hims & Hers. “The data shows our customers are experiencing good weight loss on compounded medications, having manageable side-effects through personalized dosing, suggesting the treatment is sustainable and they are making positive strides towards a healthier future. The importance of these findings is significant as we believe early customer satisfaction and adherence to treatment is likely to enhance long-term outcomes and even more important as we continue to search for ways to manage the obesity crisis in our nation.”

Download the full white paper here.

Hims & Hers

NYSE:HIMS

Release Versions

More News From Hims & Hers

Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month*

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Wegovy®**. This needle-free treatment joins a full suite of weight loss solutions designed to meet the specific needs and preferences of individual customers. By leveraging nearly a decade of infrastructur...

Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care

SAN FRANCISCO--(BUSINESS WIRE)--Today, Hims & Hers Health, Inc. (NYSE: HIMS), the leading digital health and wellness platform, launched access to the Hims & Hers Multi-Cancer Test by Galleri®, a simple cancer screening blood test that can detect a signal for 50+ types of cancer even before symptoms appear1. This multi-cancer early detection (MCED) test combines Hims & Hers’ scale with GRAIL’s innovative cancer screening technology to dramatically increase access to proactive care....

Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Monday, February 23, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international pa...
Back to Newsroom